Navigation Links
Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
Date:9/13/2011

/">www.clinicaltrials.gov.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in five Phase 2b trials, including abbreviated duration interferon and interferon-free regimens, in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice: +1 (609) 865-0693Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be s
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Announces Two-for-One Forward Stock Split
2. Pharmasset to Present at Canaccord Genuity Growth Conference
3. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
4. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
7. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
8. Pharmasset to Webcast an Investor Event From the EASL Meeting
9. Pharmasset to Present at Three Upcoming Investor Conferences
10. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
11. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  Recognizing the unique position Massachusetts ... the most respected organizations in the New England medtech community, ... Industry Council (MassMEDIC), have partnered to celebrate the region,s ... Annual Massachusetts Medtech Week. This celebration will take place May ... Center in Boston . For more information ...
(Date:4/27/2015)... Mass. , April 27, 2015 ... a collaboration with Brainlab AG, a leading software-driven ... planning and surgical navigation. The collaboration provides patients ... Stimulation (DBS) therapy. DBS is intended to treat ... help reduce symptoms for movement disorders such as ...
(Date:4/27/2015)... , April 27, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... the United States Food and Drug Administration ("FDA") verifying ... in place following the warning letter it received from ... letter follows a re-inspection in March 2015 by the ...
Breaking Medicine Technology:First Annual Massachusetts Medtech Week Celebrated this May 2First Annual Massachusetts Medtech Week Celebrated this May 3Boston Scientific Announces Strategic Collaboration With Brainlab AG 2Boston Scientific Announces Strategic Collaboration With Brainlab AG 3Boston Scientific Announces Strategic Collaboration With Brainlab AG 4CryoLife Announces Resolution of FDA Warning Letter 2
... for,rheumatoid arthritis (RA) have ushered in a new ... The findings are,reported in a New Drug Class ... of The Lancet. , RA is the most ... of the,population in the industrialised world. Its typical ...
... WIRE)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ: EPIX) ... of PRX-00023, a novel long-acting 5-HT1A agonist,was featured ... New,Clinical Drug Evaluation Unit (NCDEU) Meeting in Boca ... Institutes of,Health and the American Society of Clinical ...
Cached Medicine Technology:Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 Fitness ... the Nation, is starting a health and fitness revolution, ... the fight against obesity. For several years, Houston, the ... one of the fattest cities in America. With help ... and make it one of the fittest and healthiest ...
(Date:4/27/2015)... Los Angeles, CA (PRWEB) April 27, 2015 ... titled “How to Get Rid of Stretch Marks ,” ... stretch marks . Stretch marks are a ... women. Stretch marks are caused by a breakdown of the ... beneath the epidermis. (see: goo.gl/iRdmEe) , “Stretch mark removal ...
(Date:4/27/2015)... According to a recent report from NIDCR ... back pain, TMJ disorders are the second most ... In addition, the report revealed that TMJ disorders affect ... an estimated 4 billion dollars annually. , These estimates ... unrelated symptoms such as headaches, neck pain, tenderness of ...
(Date:4/27/2015)... Thanks to a $7.5 million grant ... half-dozen institutions, including American University, will operate in a ... and behavioral research aimed at ending the AIDS epidemic. ... with HIV or AIDS, according to the latest statistics. ... population over the age of 13 was living with ...
(Date:4/27/2015)... 27, 2015 Doctors on Liens ... a lien basis for over twenty years. So when attorneys ... best doctor in the Fresno area , Doctors on ... and his team of medical specialists. With a medical ... therapist, Dilanchian Chiropractic is now helping more personal ...
Breaking Medicine News(10 mins):Health News:Houston Celebrities Take a Stand and Rebel Against Obesity 2Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2
... a recognized leader in providing turnkey electronic billing ... announced today that it has signed an agreement ... Corporation, to provide electronic clearinghouse services for Aon ... will enable Aon eSolutions, clients and medical providers ...
... highlights new hospitalist HIDI(TM) process at the 2009 ... ExecutivesSEATTLE, March 23 Hospital executives find themselves ... percent of America,s hospitals now operating at a ... Hospital leaders seek to control costs while maintaining ...
... Adds Advanced Drug Safety and Risk Management Applications to Extend ... News Facts , , ... that it has agreed to acquire Relsys International, Inc. ("Relsys"), ... with advanced analytics for the health sciences industry. , ...
... Volumes Seen in Houston Physician-Owned Hospitals, According ... 23 HealthLeaders-InterStudy, a leading provider of ... Texas laws favoring physicians have traditionally enabled ... directly with health systems, these regulations may ...
... (Nasdaq: WBMD ), the leading provider of ... a long-term strategic relationship with Boots UK Limited, the ... Kingdom, to jointly develop a consumer health and wellness ... will leverage WebMD,s online consumer health assets and expertise ...
... 23 Dr. Kevin Polk, a clinical psychologist with ... offering a new web program and DVD for stress ... Training (ACT). It emphasizes decreasing struggling with stress and ... traditional stress management techniques such as deep breathing and ...
Cached Medicine News:Health News:WorkCompEDI Announces Agreement with Aon eSolutions for Electronic Billing Services 2Health News:Sound Inpatient Physicians Report on New Clinical Processes to Reduce Healthcare Costs and Enhance Care 2Health News:Oracle Buys Relsys 2Health News:Oracle Buys Relsys 3Health News:In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 3Health News:Surfing Your Stress to Success Program Offers a New Way of Dealing with Stress 2
Set of six replacement burrs for E0824 Storz corneal burr set. Dull finish. Most popular size or model....
Replacement burr for E0819A or E0819B Algerbrush rust ring remover. Dull finish....
0.5 mm replacement burr for Algerbrush rust ring remover (E0815 A). Burr can also be used with Algerbrush rust ring remover (E0815 B). Dull finish....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Medicine Products: